Core Viewpoint - GRI Bio, Inc. is a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases, highlighting its innovative pipeline and participation in the Virtual Investor "Top 5 for '25" On-Demand Conference [1][2]. Company Overview - GRI Bio is a clinical-stage biopharmaceutical company aiming to transform the treatment of inflammatory, fibrotic, and autoimmune diseases by targeting NKT cells, which play a crucial role in the inflammatory response [3]. - The company's lead program, GRI-0621, is an inhibitor of iNKT cell activity, being developed as a novel oral therapeutic for idiopathic pulmonary fibrosis, a disease with significant unmet medical needs [3]. - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and possesses a library of over 500 proprietary compounds to support its growing pipeline [3].
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference